{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:33:35Z","timestamp":1781649215278,"version":"3.54.5"},"reference-count":8,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A patient with advanced bladder cancer received antitumor therapy consisting of gemcitabine on days 1 and 8 combined with cisplatin and treliprimab on day 1. Severe periorbital hyperpigmentation occurred 30\u2009min after gemcitabine infusion on day 8. Symmetrical diffuse hyperpigmentation of a dark brown hue with indistinct borders appeared around the affected eye, extending to the orbital and facial regions along the orbital margin. No accompanying symptoms, including pruritus, pain, or desquamation, were observed. The patient had no prior history of dermatological conditions and no family history of skin disorders. During chemotherapy, no other drugs, cosmetics, or specific foods known to induce skin hyperpigmentation were used. No additional abnormalities were identified during dermatological examination. Laboratory tests, including liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within the range of 10\u201340\u2009IU\/L, kidney function parameters such as blood urea nitrogen (BUN) 2.8\u20137.1\u2009mmol\/L and creatinine 50\u201396 \u03bcmol\/L, blood glucose levels of 3.9\u20136.1\u2009mmol\/L, thyroid function within normal limits, and electrolytes including sodium (Na) 135\u2013145\u2009mmol\/L and potassium (K) 3.5\u20135.5\u2009mmol\/L, were all within their respective normal ranges. Considering the patient's medical background, treatment regimen, and the temporal relationship between the onset of symptoms and chemotherapy cycles, this periorbital hyperpigmentation likely represents a transient adverse reaction to gemcitabine, as supported by previously reported cases. Within 2\u2009days after chemotherapy cessation, the periorbital hyperpigmentation improved significantly. This case highlights that during gemcitabine administration, clinicians should remain vigilant for rare adverse reaction of gemcitabine\u2010induced periorbital hyperpigmentation. Close skin monitoring throughout treatment is essential, and prompt evaluation and intervention should be carried out to improve the patient's quality of life.<\/jats:p>","DOI":"10.1002\/ccr3.72641","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:48:46Z","timestamp":1778734126000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4421-1044","authenticated-orcid":false,"given":"Li","family":"Juan","sequence":"first","affiliation":[{"name":"Macau University of Science and Technology  Macau China"},{"name":"The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine  Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Weiping","sequence":"additional","affiliation":[{"name":"Macau University of Science and Technology  Macau China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"28","key":"e_1_2_13_2_1","first-page":"3462","article-title":"International Phase III Study of Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Advanced or Metastatic Bladder Cancer Who Are Ineligible for Cisplatin Alone: The GETUG\u2010AFU 0501 Trial","volume":"30","author":"Bellmunt J.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"38","key":"e_1_2_13_3_1","first-page":"631","article-title":"Chemotherapy\u2010Induced Skin Reactions","volume":"110","author":"Jordan K.","year":"2013","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"5","key":"e_1_2_13_4_1","first-page":"625","article-title":"Chemotherapy\u2010Induced Hyperpigmentation: A Review of Pathophysiology, Clinical Features and Treatment","volume":"79","author":"Puvvala C. K.","year":"2013","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"3","key":"e_1_2_13_5_1","first-page":"327","article-title":"Gemcitabine\u2010Induced Skin Toxicity: A Review of the Literature","volume":"45","author":"N\u00f8rgaard M.","year":"2006","journal-title":"Acta Oncologica"},{"issue":"3","key":"e_1_2_13_6_1","first-page":"433","article-title":"Cutaneous Adverse Reactions to Gemcitabine: A Retrospective Analysis of 100 Patients","volume":"89","author":"Pinto A. P.","year":"2014","journal-title":"Anais Brasileiros de Dermatologia"},{"issue":"10","key":"e_1_2_13_7_1","first-page":"876","article-title":"Gemcitabine\u2010Induced Cutaneous Adverse Reactions: A Single\u2010Center Experience","volume":"37","author":"Park Y. M.","year":"2010","journal-title":"Journal of Dermatology"},{"issue":"4","key":"e_1_2_13_8_1","first-page":"758","article-title":"Gemcitabine\u2010Induced Skin Eruptions: A Case Report and Review of the Literature","volume":"140","author":"Shiohara T.","year":"1999","journal-title":"British Journal of Dermatology"},{"issue":"04","key":"e_1_2_13_9_1","first-page":"486","article-title":"Analysis of Adverse Drug Reactions and Risk Factors of Gemcitabine in Inner Mongolia Region [J]","volume":"36","author":"Shengnan Y.","year":"2025","journal-title":"China Pharmacy"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.72641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.72641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.72641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:48:57Z","timestamp":1778734137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.72641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/ccr3.72641"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.72641","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.176880795.55266519\/v1","asserted-by":"object"}]},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72641"}}